Efficacy and Safety of Ketamine to Treat Cancer Pain in Adult Patients: A Systematic Review

氯胺酮 医学 癌症疼痛 麻醉 恶心 止痛药 可视模拟标度 镇静 便秘 随机对照试验 不利影响 呕吐 癌症 外科 内科学
作者
Jiao Jiao,J Fan,Yonggang Zhang,Lingmin Chen
出处
期刊:Journal of Pain and Symptom Management [Elsevier BV]
卷期号:67 (3): e185-e210 被引量:6
标识
DOI:10.1016/j.jpainsymman.2023.11.004
摘要

Context Ketamine is a well-characterised anaesthetic agent, and subanesthetic ketamine possesses analgesic effects in both acute and chronic pain. Objectives A systematic review was performed to ascertain the efficacy and safety of ketamine in treating pain for cancer patients. Methods Eight databases were searched from the inception to March 20th, 2023 to obtain randomised controlled trials (RCTs) on ketamine for treating pain in cancer patients. Two reviewers independently screened studies, extracted the data and assessed the risk of bias of included studies; then, meta-analysis was performed by using Revman 5.3 software and Stata 14.0 software. Results 35 studies were included, involving 2279 patients with cancer pain. The results of meta-analysis showed that ketamine could significantly reduce pain intensity. Subgroup analysis revealed that, when compared with control group, ketamine decreased markedly visual analogue scale (VAS) scores in 2 days after the end of treatment with ketamine, and ketamine administrated by patient controlled epidural analgesia (PCEA) was effective. Meanwhile, ketamine could significantly reduce the number of patient-controlled analgesia (PCA) compressions within 24 hours and morphine dosage. Ketamine could not decrease Ramsay sedation score. Additionally, the adverse events significantly decreased in the ketamine group, including nausea and vomiting, constipation, pruritus, lethargy, uroschesis, hallucination, and respiratory depression. In addition, compared with the control group, ketamine could reduce Hamilton depression scale (HAMD) score and relieve depressive symptoms. Conclusion Ketamine may be used as an effective therapy to relieve cancer pain. However, more rigorously designed RCTs with larger sample sizes are required to verify the above conclusions.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
严厉的妙蛙花完成签到,获得积分10
1秒前
沉默初雪发布了新的文献求助10
1秒前
NexusExplorer应助wtt采纳,获得10
2秒前
Hello应助wtt采纳,获得10
2秒前
万能图书馆应助wtt采纳,获得10
2秒前
万能图书馆应助wtt采纳,获得10
2秒前
隐形曼青应助wtt采纳,获得10
2秒前
李爱国应助wtt采纳,获得10
2秒前
领导范儿应助wtt采纳,获得10
2秒前
2秒前
量子星尘发布了新的文献求助10
2秒前
3秒前
3秒前
老迟到的金鱼应助lihua采纳,获得20
3秒前
852应助yxy采纳,获得10
4秒前
6秒前
发nature完成签到 ,获得积分10
6秒前
7秒前
7秒前
今后应助欣慰的乌冬面采纳,获得10
9秒前
FashionBoy应助xsuvian采纳,获得10
9秒前
CodeCraft应助wtt采纳,获得10
9秒前
Owen应助wtt采纳,获得10
10秒前
bkagyin应助wtt采纳,获得10
10秒前
大模型应助wtt采纳,获得10
10秒前
脑洞疼应助wtt采纳,获得10
10秒前
Lucas应助wtt采纳,获得10
10秒前
脑洞疼应助wtt采纳,获得10
10秒前
大模型应助wtt采纳,获得10
10秒前
上官若男应助wtt采纳,获得10
10秒前
我是老大应助wtt采纳,获得10
10秒前
12秒前
13秒前
桐桐应助notsoeasy采纳,获得10
15秒前
15秒前
16秒前
16秒前
Jungel完成签到,获得积分0
16秒前
16秒前
17秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975661
求助须知:如何正确求助?哪些是违规求助? 3520000
关于积分的说明 11200535
捐赠科研通 3256410
什么是DOI,文献DOI怎么找? 1798247
邀请新用户注册赠送积分活动 877490
科研通“疑难数据库(出版商)”最低求助积分说明 806390